Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

US FDA approves Novo Nordisk’s Wegovy to treat metabolic dysfunction-associated steatohepatitis: Bagsværd, Denmark Monday, August 18, 2025, 11:00 Hrs [IST] Novo Nordisk, a lead ...

Shares of Danish pharmaceutical company Novo Nordisk ($NVO) rose on Friday after the U.S. Food and Drug Administration (FDA) granted accelerated ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

While Novo Nordisk say they're fighting against stigma, critics say they could be promoting prescription drugs under the ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...